Charles River Laboratories International stock is trading -29.68% below its average target price of $236.08 after dropping -3.8% during today's afternoon session. Analysts are giving the large-cap Biotechnology company an average rating of buy and target prices ranging from $207.0 to $275.0 per share.
Charles River Laboratories International's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 3.9%. The stock's short ratio is 3.5. Only 0.98% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders.
Another number to watch is the company's rate of institutional share ownership, which now stands at 101.8%. In conclusion, we believe there is mixed market sentiment regarding Charles River Laboratories International.
Institutions Invested in Charles River Laboratories International
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-06-30 | Vanguard Group Inc | 12% | 5,924,378 | $983,446,748 |
| 2023-06-30 | Blackrock Inc. | 10% | 5,198,037 | $862,874,142 |
| 2023-06-30 | Price (T.Rowe) Associates Inc | 5% | 2,496,494 | $414,418,004 |
| 2023-06-30 | State Street Corporation | 4% | 2,091,017 | $347,108,822 |
| 2023-06-30 | ClearBridge Investments, LLC | 3% | 1,750,110 | $290,518,260 |
| 2023-06-30 | Kayne Anderson Rudnick Investment Management LLC | 3% | 1,681,120 | $279,065,920 |
| 2023-09-30 | Allspring Global Investments Holdings, LLC | 2% | 1,195,226 | $198,407,516 |
| 2023-06-30 | Geode Capital Management, LLC | 2% | 1,101,400 | $182,832,400 |
| 2023-06-30 | Ariel Investments, LLC | 2% | 1,047,840 | $173,941,440 |
| 2023-09-30 | Mackenzie Financial Corporation | 2% | 923,649 | $153,325,734 |
